» Articles » PMID: 23484019

WNT5A Inhibits Metastasis and Alters Splicing of Cd44 in Breast Cancer Cells

Overview
Journal PLoS One
Date 2013 Mar 14
PMID 23484019
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Wnt5a is a non-canonical signaling Wnt. Low expression of WNT5A is correlated with poor prognosis in breast cancer patients. The highly invasive breast cancer cell lines, MDA-MB-231 and 4T1, express very low levels of WNT5A. To determine if enhanced expression of WNT5A would affect metastatic behavior, we generated WNT5A expressing cells from the 4T1 and MDA-MB-231 parental cell lines. WNT5A expressing cells demonstrated cobblestone morphology and reduced in vitro migration relative to controls. Cell growth was not altered. Metastasis to the lung via tail vein injection was reduced in the 4T1-WNT5A expressing cells relative to 4T1-vector controls. To determine the mechanism of WNT5A action on metastasis, we performed microarray and whole-transcriptome sequence analysis (RNA-seq) to compare gene expression in 4T1-WNT5A and 4T1-vector cells. Analysis indicated highly significant alterations in expression of genes associated with cellular movement. Down-regulation of a subset of these genes, Mmp13, Nos2, Il1a, Cxcl2, and Lamb3, in WNT5A expressing cells was verified by semi-quantitative RT-PCR. Significant differences in transcript splicing were also detected in cell movement associated genes including Cd44. Cd44 is an adhesion molecule with a complex genome structure. Variable exon usage is associated with metastatic phenotype. Alternative spicing of Cd44 in WNT5A expressing cells was confirmed using RT-PCR. We conclude that WNT5A inhibits metastasis through down-regulation of multiple cell movement pathways by regulating transcript levels and splicing of key genes like Cd44.

Citing Articles

9S1R nullomer peptide induces mitochondrial pathology, metabolic suppression, and enhanced immune cell infiltration, in triple-negative breast cancer mouse model.

Ali N, Wolf C, Kanchan S, Veerabhadraiah S, Bond L, Turner M Biomed Pharmacother. 2023; 170:115997.

PMID: 38118350 PMC: 10872342. DOI: 10.1016/j.biopha.2023.115997.


RNA-binding proteins regulating the CD44 alternative splicing.

Maltseva D, Tonevitsky A Front Mol Biosci. 2023; 10:1326148.

PMID: 38106992 PMC: 10722200. DOI: 10.3389/fmolb.2023.1326148.


WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice.

Xue W, Cai L, Li S, Hou Y, Wang Y, Yang D Discov Oncol. 2023; 14(1):136.

PMID: 37486552 PMC: 10366069. DOI: 10.1007/s12672-023-00739-7.


Nullomer peptide increases immune cell infiltration and reduces tumor metabolism in triple negative breast cancer mouse model.

Ali N, Wolf C, Kanchan S, Veerabhadraiah S, Bond L, Turner M Res Sq. 2023; .

PMID: 37461536 PMC: 10350184. DOI: 10.21203/rs.3.rs-3097552/v1.


The role of prickle proteins in vertebrate development and pathology.

Radaszkiewicz K, Sulcova M, Kohoutkova E, Harnos J Mol Cell Biochem. 2023; 479(5):1199-1221.

PMID: 37358815 PMC: 11116189. DOI: 10.1007/s11010-023-04787-z.


References
1.
Carpenter P, Dao A, Arain Z, Chang M, Nguyen H, Arain S . Motility induction in breast carcinoma by mammary epithelial laminin 332 (laminin 5). Mol Cancer Res. 2009; 7(4):462-75. DOI: 10.1158/1541-7786.MCR-08-0148. View

2.
Jonsson M, Andersson T . Repression of Wnt-5a impairs DDR1 phosphorylation and modifies adhesion and migration of mammary cells. J Cell Sci. 2001; 114(Pt 11):2043-53. DOI: 10.1242/jcs.114.11.2043. View

3.
Katoh M . WNT/PCP signaling pathway and human cancer (review). Oncol Rep. 2005; 14(6):1583-8. View

4.
Benhaj K, Akcali K, Ozturk M . Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep. 2006; 15(3):701-7. View

5.
Reis-Filho J, Pusztai L . Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011; 378(9805):1812-23. DOI: 10.1016/S0140-6736(11)61539-0. View